Trials / Completed
CompletedNCT01472757
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 374 (actual)
- Sponsor
- Vectura Limited · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the clinical efficacy of three doses of VR506 delivered via a new dry powder inhaler for the treatment of asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VR506 | VR506 inhalation powder delivered via a new dry powder inhaler |
| DRUG | Placebo | Placebo delivered via a new dry powder inhaler |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2011-11-16
- Last updated
- 2020-04-21
- Results posted
- 2020-04-21
Locations
82 sites across 5 countries: United States, Philippines, Poland, Romania, Ukraine
Source: ClinicalTrials.gov record NCT01472757. Inclusion in this directory is not an endorsement.